831 related articles for article (PubMed ID: 26409014)
21. An evaluation of the levonorgestrel-releasing IUD: its advantages and disadvantages when compared to the copper-releasing IUDs.
Chi IC
Contraception; 1991 Dec; 44(6):573-88. PubMed ID: 1773615
[TBL] [Abstract][Full Text] [Related]
22. Contraception with two levonorgestrel rod implants. A 5-year study in the United States and Dominican Republic.
Sivin I; Alvarez F; Mishell DR; Darney P; Wan L; Brache V; Lacarra M; Klaisle C; Stern J
Contraception; 1998 Nov; 58(5):275-82. PubMed ID: 9883382
[TBL] [Abstract][Full Text] [Related]
23. Long-term contraception with the levonorgestrel 20 mcg/day (LNg 20) and the copper T 380Ag intrauterine devices: a five-year randomized study.
Sivin I; el Mahgoub S; McCarthy T; Mishell DR; Shoupe D; Alvarez F; Brache V; Jimenez E; Diaz J; Faundes A
Contraception; 1990 Oct; 42(4):361-78. PubMed ID: 2124179
[TBL] [Abstract][Full Text] [Related]
24. Hormonal intrauterine devices.
Rybo G; Andersson K; Odlind V
Ann Med; 1993 Apr; 25(2):143-7. PubMed ID: 8489751
[TBL] [Abstract][Full Text] [Related]
25. Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel-releasing intrauterine system.
Suvisaari J; Lähteenmäki P
Contraception; 1996 Oct; 54(4):201-8. PubMed ID: 8922872
[TBL] [Abstract][Full Text] [Related]
26. Free-of-charge long-acting reversible contraception: two-year discontinuation, its risk factors, and reasons.
Saloranta TH; Gyllenberg FK; But A; Gissler M; Laine MK; Heikinheimo O
Am J Obstet Gynecol; 2020 Dec; 223(6):886.e1-886.e17. PubMed ID: 32562657
[TBL] [Abstract][Full Text] [Related]
27. Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial.
Papaikonomou K; Kopp Kallner H; Söderdahl F; Gemzell-Danielsson K
Hum Reprod; 2018 Nov; 33(11):2002-2009. PubMed ID: 30295731
[TBL] [Abstract][Full Text] [Related]
28. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration.
McNicholas C; Swor E; Wan L; Peipert JF
Am J Obstet Gynecol; 2017 Jun; 216(6):586.e1-586.e6. PubMed ID: 28147241
[TBL] [Abstract][Full Text] [Related]
29. Risks and benefits, advantages and disadvantages of levonorgestrel-releasing contraceptive implants.
Sivin I
Drug Saf; 2003; 26(5):303-35. PubMed ID: 12650633
[TBL] [Abstract][Full Text] [Related]
30. A systematic review on clinical effectiveness, side-effect profile and meta-analysis on continuation rate of etonogestrel contraceptive implant.
Moray KV; Chaurasia H; Sachin O; Joshi B
Reprod Health; 2021 Jan; 18(1):4. PubMed ID: 33407632
[TBL] [Abstract][Full Text] [Related]
31. Immediate versus delayed insertion of an etonogestrel releasing implant at medical abortion-a randomized controlled equivalence trial.
Hognert H; Kopp Kallner H; Cameron S; Nyrelli C; Jawad I; Heller R; Aronsson A; Lindh I; Benson L; Gemzell-Danielsson K
Hum Reprod; 2016 Nov; 31(11):2484-2490. PubMed ID: 27664217
[TBL] [Abstract][Full Text] [Related]
32. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties.
Luukkainen T; Toivonen J
Contraception; 1995 Nov; 52(5):269-76. PubMed ID: 8585882
[TBL] [Abstract][Full Text] [Related]
33. Control of endometriosis-associated pain with etonogestrel-releasing contraceptive implant and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial.
Carvalho N; Margatho D; Cursino K; Benetti-Pinto CL; Bahamondes L
Fertil Steril; 2018 Nov; 110(6):1129-1136. PubMed ID: 30396557
[TBL] [Abstract][Full Text] [Related]
34. Acceptability of the levonorgestrel releasing-intrauterine system and etonogestrel implant: one-year results of an observational study.
Short M; Dallay D; Omokanye S; Hanisch JU; Inki P
Eur J Contracept Reprod Health Care; 2012 Feb; 17(1):79-88. PubMed ID: 22200172
[TBL] [Abstract][Full Text] [Related]
35. The effects of Implanon on lipid metabolism in comparison with Norplant.
Suherman SK; Affandi B; Korver T
Contraception; 1999 Nov; 60(5):281-7. PubMed ID: 10717780
[TBL] [Abstract][Full Text] [Related]
36. Body weight and composition in users of levonorgestrel-releasing intrauterine system.
Dal'Ava N; Bahamondes L; Bahamondes MV; de Oliveira Santos A; Monteiro I
Contraception; 2012 Oct; 86(4):350-3. PubMed ID: 22445431
[TBL] [Abstract][Full Text] [Related]
37. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices.
Heinemann K; Reed S; Moehner S; Minh TD
Contraception; 2015 Apr; 91(4):280-3. PubMed ID: 25601350
[TBL] [Abstract][Full Text] [Related]
38. Hormonally impregnated intrauterine systems (IUSs) versus other forms of reversible contraceptives as effective methods of preventing pregnancy.
French R; Van Vliet H; Cowan F; Mansour D; Morris S; Hughes D; Robinson A; Proctor T; Summerbell C; Logan S; Helmerhorst F; Guillebaud J
Cochrane Database Syst Rev; 2004; 2004(3):CD001776. PubMed ID: 15266453
[TBL] [Abstract][Full Text] [Related]
39. Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion.
Steinauer JE; Upadhyay UD; Sokoloff A; Harper CC; Diedrich JT; Drey EA
Contraception; 2015 Dec; 92(6):553-9. PubMed ID: 26093190
[TBL] [Abstract][Full Text] [Related]
40. Emergency contraception with a copper IUD or oral levonorgestrel: an observational study of 1-year pregnancy rates.
Turok DK; Jacobson JC; Dermish AI; Simonsen SE; Gurtcheff S; McFadden M; Murphy PA
Contraception; 2014 Mar; 89(3):222-8. PubMed ID: 24332433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
